BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sell to Hold. Analyst Price Forecast Suggests 10.64% Upside As of ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Treasury yields are pushing higher amid another rally in energy prices; market mea sures of inflation expectations have reached their highest level since early-2023. Elsewhere, Magnificent Seven ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Initial public offerings in the U.S. are poised for a strong comeback after nearly three years of sluggish activity, with ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Police were seen walking down a path between the supermarket and the former Tortilla Flat restaurant Monday morning.

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

This was the stock's second consecutive day of losses.

RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...